Cargando…

A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disorder of the central nervous system caused by opportunistic infection of the JC virus (JCV). CASE PRESENTATION: A 58-year-old Japanese woman was admitted to our hospital for aphasia. She had a 5-year histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagahori, Takashi, Shiraishi, Wataru, Nishikawa, Masafumi, Matsuyoshi, Ayano, Ogura, Takenori, Yamada, Yui, Takahashi, Kenta, Suzuki, Tadaki, Nakamichi, Kazuo, Hashimoto, Tetsuya, Hatano, Taketo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893603/
https://www.ncbi.nlm.nih.gov/pubmed/36726087
http://dx.doi.org/10.1186/s12883-023-03094-w
_version_ 1784881561184763904
author Nagahori, Takashi
Shiraishi, Wataru
Nishikawa, Masafumi
Matsuyoshi, Ayano
Ogura, Takenori
Yamada, Yui
Takahashi, Kenta
Suzuki, Tadaki
Nakamichi, Kazuo
Hashimoto, Tetsuya
Hatano, Taketo
author_facet Nagahori, Takashi
Shiraishi, Wataru
Nishikawa, Masafumi
Matsuyoshi, Ayano
Ogura, Takenori
Yamada, Yui
Takahashi, Kenta
Suzuki, Tadaki
Nakamichi, Kazuo
Hashimoto, Tetsuya
Hatano, Taketo
author_sort Nagahori, Takashi
collection PubMed
description BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disorder of the central nervous system caused by opportunistic infection of the JC virus (JCV). CASE PRESENTATION: A 58-year-old Japanese woman was admitted to our hospital for aphasia. She had a 5-year history of untreated sarcoidosis and was a human T cell lymphotropic virus-1 (HTLV-1) carrier. Serum angiotensin-converting enzyme, soluble interleukin-2 receptor, lysozyme, and calcium levels were elevated. JCV-DNA was not detected in cerebrospinal fluid by PCR testing. Skin biopsy revealed noncaseating granuloma formation. Bilateral multiple nodular lesions were present on chest X-ray. Brain magnetic resonance imaging showed left frontal and temporal lesions without gadolinium enhancement. As we suspected that systemic sarcoidosis had developed into neurosarcoidosis, we started steroid and infliximab administration. After treatment, the chest X-ray and serum abnormalities ameliorated, but the neurological deficits remained. At 1 month after immunotherapy, she developed right hemiparesis. Cerebrospinal fluid was positive for prototype (PML-type) JCV on repeated PCR testing. Brain biopsy revealed demyelinating lesions with macrophage infiltration, atypical astrocytes, and JCV antigen-positive cells. We diagnosed her with PML and started mefloquine, leading to partial remission. CONCLUSIONS: Sarcoidosis and HTLV-1 infection both affect T cell function, especially CD4(+) T cells, and may developped the patient’s PML. The comorbidity of sarcoidosis, PML, and HTLV-1 infection has not been reported, and this is the world’s first report of PML associated with HTLV-1 infection and sarcoidosis.
format Online
Article
Text
id pubmed-9893603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98936032023-02-03 A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report Nagahori, Takashi Shiraishi, Wataru Nishikawa, Masafumi Matsuyoshi, Ayano Ogura, Takenori Yamada, Yui Takahashi, Kenta Suzuki, Tadaki Nakamichi, Kazuo Hashimoto, Tetsuya Hatano, Taketo BMC Neurol Case Report BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disorder of the central nervous system caused by opportunistic infection of the JC virus (JCV). CASE PRESENTATION: A 58-year-old Japanese woman was admitted to our hospital for aphasia. She had a 5-year history of untreated sarcoidosis and was a human T cell lymphotropic virus-1 (HTLV-1) carrier. Serum angiotensin-converting enzyme, soluble interleukin-2 receptor, lysozyme, and calcium levels were elevated. JCV-DNA was not detected in cerebrospinal fluid by PCR testing. Skin biopsy revealed noncaseating granuloma formation. Bilateral multiple nodular lesions were present on chest X-ray. Brain magnetic resonance imaging showed left frontal and temporal lesions without gadolinium enhancement. As we suspected that systemic sarcoidosis had developed into neurosarcoidosis, we started steroid and infliximab administration. After treatment, the chest X-ray and serum abnormalities ameliorated, but the neurological deficits remained. At 1 month after immunotherapy, she developed right hemiparesis. Cerebrospinal fluid was positive for prototype (PML-type) JCV on repeated PCR testing. Brain biopsy revealed demyelinating lesions with macrophage infiltration, atypical astrocytes, and JCV antigen-positive cells. We diagnosed her with PML and started mefloquine, leading to partial remission. CONCLUSIONS: Sarcoidosis and HTLV-1 infection both affect T cell function, especially CD4(+) T cells, and may developped the patient’s PML. The comorbidity of sarcoidosis, PML, and HTLV-1 infection has not been reported, and this is the world’s first report of PML associated with HTLV-1 infection and sarcoidosis. BioMed Central 2023-02-02 /pmc/articles/PMC9893603/ /pubmed/36726087 http://dx.doi.org/10.1186/s12883-023-03094-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Nagahori, Takashi
Shiraishi, Wataru
Nishikawa, Masafumi
Matsuyoshi, Ayano
Ogura, Takenori
Yamada, Yui
Takahashi, Kenta
Suzuki, Tadaki
Nakamichi, Kazuo
Hashimoto, Tetsuya
Hatano, Taketo
A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
title A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
title_full A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
title_fullStr A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
title_full_unstemmed A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
title_short A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
title_sort human t-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893603/
https://www.ncbi.nlm.nih.gov/pubmed/36726087
http://dx.doi.org/10.1186/s12883-023-03094-w
work_keys_str_mv AT nagahoritakashi ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT shiraishiwataru ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT nishikawamasafumi ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT matsuyoshiayano ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT oguratakenori ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT yamadayui ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT takahashikenta ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT suzukitadaki ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT nakamichikazuo ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT hashimototetsuya ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT hatanotaketo ahumantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT nagahoritakashi humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT shiraishiwataru humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT nishikawamasafumi humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT matsuyoshiayano humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT oguratakenori humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT yamadayui humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT takahashikenta humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT suzukitadaki humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT nakamichikazuo humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT hashimototetsuya humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport
AT hatanotaketo humantlymphotropicvirus1carrierwhodevelopedprogressivemultifocalleukoencephalopathyfollowingimmunotherapyforsarcoidosisacasereport